Figure 2. CM-118 inhibits proliferation of c-Met- or ALK-driven cancer cell lines. Panels of 5 NSCLC (A, left), 5 gastric (B, left), and 4 brain (C, left) cancer lines were immunoblotted as indicated. CM-118 was assessed for growth inhibition potency in corresponding cancer lines. Bar graphs show mean IC₅₀ values (n = 3) determined from MTS assays for NSCLC (A, right), gastric (B, right), and brain (C, right) panels.